J Pediatr Clin Pract. 2025 Jul 7;17:200161. doi: 10.1016/j.jpedcp.2025.200161. eCollection 2025 Sep.
ABSTRACT
Sirolimus is reportedly effective for kaposiform hemangioendothelioma. However, data on the efficacy of low-dose sirolimus therapy remain limited. This report presents two cases of neonatal and infantile kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon successfully treated with low-dose sirolimus (serum level: 2-6 ng/mL) without any adverse events.
PMID:40703620 | PMC:PMC12284785 | DOI:10.1016/j.jpedcp.2025.200161
